RxDoctor Payments Data

Rebecca Hammond

Family · Wilmington, DENPI 1861896532

Payments from drug & device makers

$550in general payments, 2019–2025

Across 18 payments — averaging $30.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$125
  • Regeneron$117
  • Novo Nordisk$114
  • Lilly USA, LLC$48
  • Genentech USA, Inc.$43
  • Pfizer$43
  • plus $60 from 3 others

What the payments were for

  • Food & beverage$550100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$550 in reported general payments places this provider in the 50th percentile of 523 family providers in Delaware.

See all family providers in Delaware

Medicare billing

Part B allowed, 2024
$156,107
Medicare patients
322
Services billed
1,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban135$56,200
XareltoRivaroxaban33$18,193
JardianceEmpagliflozin42$18,092
ArexvyRsvpref3 Antigen/As01e/Pf56$16,926
MounjaroTirzepatide29$15,844
TrulicityDulaglutide11$12,176
JanumetSitagliptin Phos/Metformin Hcl14$8,034
MyrbetriqMirabegron14$6,641
BrilintaTicagrelor30$6,582
Sucralfate39$5,842
Incruse ElliptaUmeclidinium Bromide11$4,856
Gabapentin231$4,758
Atorvastatin Calcium296$4,012
Lantus SolostarInsulin Glargine,hum.Rec.Anlog74$3,931
MovantikNaloxegol Oxalate14$2,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$43$58,801148 claims
Lilly USA, LLCMounjaro, Trulicity$48$28,02040 claims
Astellas Pharma US IncMyrbetriq$15$6,64114 claims
AstraZenecaBrilinta$125$6,58230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 523 family providers in Delaware.

Other family in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →